Kairos Discovery

Kairos Discovery is a biotechnology company, founded in 2022 and based in Lyon, France, that is focused on the development of a new class of targeted therapies for precision oncology. The firm leverages its expertise in medicinal chemistry and drug discovery to create patented small therapeutic molecules.

The company's discovery platform is engineered to design highly selective covalent medicines. This approach targets both well-validated but difficult-to-drug targets and novel biological targets, aiming to overcome the limitations associated with conventional kinase inhibition in cancer treatment.

Kairos Discovery's business model centers on advancing its proprietary molecules through the preclinical and up to the clinical stages of development. The primary market is the oncology sector, with a focus on providing new therapeutic options for patients through precision medicine.

Keywords: targeted therapies, precision oncology, small molecules, drug discovery, covalent medicines, kinase inhibition, medicinal chemistry, cancer treatment, biotechnology, clinical stages